Cross-reactive antibody responses were detected with vaccines for Zaire Ebola virus disease

The trial could begin within two weeks if it receives regulatory and ethical approval, the Addis Ababa-based agency said in an email Sunday.

New data supports the idea that Merck’s Ebola vaccine Ervebo, licensed to target the Zaire species of ebolaviruses, could also offer some protection against another.